Excluded Drug Criteria. Coverage Duration. Age Restrictions. Prescriber Restrictions. Prior Authorization Type Description.
|
|
- Allan Ray
- 8 years ago
- Views:
Transcription
1 2015 Cigna-HealthSpring - H Cigna-HealthSpring Preferred (HMO), Cigna-HealthSpring Achieve Plus (HMO SNP), Cigna- HealthSpring Preferred Plus (HMO) (Updated December 2015) Name Other ABELCET ABRAXANE ACETYLCYSTEINE ACTEMRA ACTEMRA Documentation of diagnosis and past medication history. Treatment of rheumatoid arthritis (RA) when ANY of the following criteria are met: 1) history of positive clinical response to tocilizumab therapy OR 2) inadequate response, intolerance, or contraindication to at least one disease-modifying anti-rheumatic drug (DMARD) (i.e., Methotrexate (MTX) Azathioprine, gold, Hydroxychloroquine, Penicillamine, Sulfasalazine). For RA new starts that meet the above criteria, the patient must also have failure, contraindication or intolerance to Enbrel or Humira before authorization of Actemra. BvsD Determinaton ACTHAR HP ACTHAR HP All FDA-approved excluded from part D. For the treatment of multiple sclerosis the patient must have failure, contraindication or intolerance to intravenous corticosteroid therapy and currently maintained on one of the following formulary drugs Avonex, Copaxone, Extavia or Rebif before Acthar HP is authorized. ACYCLOVIR SODIUM ADCIRCA ADCIRCA All FDA-approved excluded from part D. Medical documentation of pulmonary arterial hypertension. ALBUTEROL SULFATE ALIMTA ALORA HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ALOSETRON LOTRONEX Lotronex (alosetron) will not be approved for use in men, as safety and efficacy in men has not been established. must be enrolled in the prescribing program for alosetron.
2 Name Other ALOXI AMBISOME AMIFOSTINE AMINOSYN AMINOSYN 7%/ELECTROLYTES AMINOSYN 8.5%/ELECTROLYTES AMINOSYN II AMINOSYN II 8.5%/ELECTROLYTES AMINOSYN M AMINOSYN-HBC AMINOSYN-PF AMINOSYN-PF 5.2 % AMINOSYN-PF 7% AMITRIPTYLINE HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. AMPHOTERICIN B
3 Name Other AMPYRA AMPYRA Documentation of diagnosis. Ampyra is considered medically necessary for patients with multiple sclerosis with medical documentation of impaired walking ability. ANGELIQ HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ANZEMET ANZEMET INJ ARALAST NP Alpha-1 Proteinase Inhibitor Therapy All FDA-approved excluded from part D. Intravenous alpha1-proteinase inhibitor (human) is authorized for the treatment of congenital alpha1-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met: 1) alpha1-antitrypsin (AAT) concentration less than 80mg/dl or less than 11 micromolar and 2) obstructive lung disease as defined by a forced expiratory volume in one second (FEV1) of 30 to 65% of predicted or a rapid decline in lung function defined as a change in FEV1 of greater than 120ml per year. BvsD Determination. ARANESP ALBUMIN FREE ARCALYST HEMATOPOIETICS ARCALYST For the indication of anemia, documentation of Hemoglobin less than 11, Hematocrit, transferrin saturation greater than 20%, and ferritin levels greater than 100 obtained over the last 3 months. Documentation of diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). 12 years of age and older 6 months BvD Determination. Patients must also have failure, contraindication or intolerance to Procrit or Aranesp before Epogen will be authorized. BvsD Determination ARRANON ARZERRA ASCOMP/CODEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. ASTAGRAF XL AUBAGIO AUBAGIO Aubagio will be used as monotherapy for the treatment of multiple sclerosis. Patient must also have failure, contraindication or intolerance to one of the following formulary alternatives Avonex, Copaxone, Extavia or Rebif before Aubagio will be authorized. AVASTIN
4 Name AVONEX IMMUNOMODULATO RS Other AZACITIDINE AZATHIOPRINE BENLYSTA BENLYSTA The patient must have a positive autoantibody test (i.e., antinuclear antibody [ANA] greater than or equal to 1:80 and/or anti-double-stranded DNA [anti-dsdna] greater than or equal to 30 IU/ml) AND active disease state as documented by a SELENA-SLEDAI score of 6 or greater on the current treatment regimen. The patient must be receiving one standard therapy for SLE with any of the following: corticosteroids, hydroxychloroquine, immunosuppressives (cyclophosphamide, azathioprine, mycophenolate, methotrexate, cyclosporine) or nonsteroidal anti-inflammatory drugs AND there must be an absence of severe active lupus nephritis or severe active central nervous system lupus before Benlysta is authorized. BvsD Determination BENZTROPINE MESYLATE HRM - Benztropine If only one (1) safer formulary alternative is available, then only that particular medication would need to be documented as tried and failed or clinical rationale provided as to why that one safer formulary alternative is not Safer alternatives depend on indication. For Parkinsonism, safer alternatives are: Carbidopa/Levodopa, Pramipexole, Ropinirole, Bromocriptine, Amantadine, and Selegiline. For extrapyramidal symptoms, a safer alternative is: Amantadine. BERINERT BERINERT Berinert is authorized for the treatment of acute angioedema attacks with hereditary angioedema (HAE) when BOTH of the following criteria are met: 1) confirmed diagnosis of (HAE) as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER a) C1 inhibitor (C1INH) antigenic level below the lower limit 10 years and older of normal as defined by the laboratory performing the test or b) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test AND 2) history of a moderate or severe attack (e.g., airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion). BETHKIS BICNU BIVIGAM BLEOMYCIN SULFATE BONIVA
5 Name BOTOX BOTOX Exclude when used for cosmetic purposes. Documentation of diagnosis 3 months Other BROVANA BUDESONIDE BUSULFEX BUTAL/ASA/CAFF HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. BUTALBITAL/ACETA MINOPHEN HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. BUTALBITAL/ACETA MINOPHEN/CAFFEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. BUTALBITAL/ACETA MINOPHEN/CAFFEINE /CODEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen.
6 Name Other BUTALBITAL/APAP/C AFFEINE HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. CALCITRIOL CARBOPLATIN CARIMUNE NANOFILTERED CARISOPRODOL HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth CARISOPRODOL/ASPI RIN HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth CARISOPRODOL/ASPI RIN/CODEINE HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth CELLCEPT CELLCEPT INTRAVENOUS CEREZYME
7 Name Other CESAMET CHLORDIAZEPOXIDE/ AMITRIPTYLINE to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. CHLORZOXAZONE to New Starts HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. CIALIS CIALIS All FDA-approved excluded from part D. Cialis 2.5mg and 5mg are only covered for the treatment of benign prostatic hyperplasia (BPH). CINRYZE CINRYZE Patient must have a confirmed diagnosis of HAE as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER of the following: 1) C1 inhibitor (C1INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test 2) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test or 3) known HAE-causing C1INH mutation. The patient must have a history of more than one severe event per month and have failure, contraindication or intolerance to one conventional therapy for HAE prophylaxis such as aminocaproic acid, danazol or tranexamic acid. CISPLATIN CLADRIBINE CLIMARA PRO HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. CLINIMIX 2.75%/DEXTROSE 5% CLINIMIX 4.25%/DEXTROSE 10%
8 Name Other CLINIMIX 4.25%/DEXTROSE 20% CLINIMIX 4.25%/DEXTROSE 25% CLINIMIX 4.25%/DEXTROSE 5% CLINIMIX 5%/DEXTROSE 15% CLINIMIX 5%/DEXTROSE 20% CLINIMIX 5%/DEXTROSE 25% CLINIMIX E 2.75%/DEXTROSE 10% CLINIMIX E 2.75%/DEXTROSE 5% CLINIMIX E 4.25%/DEXTROSE 25% CLINIMIX E 4.25%/DEXTROSE 5% CLINIMIX E 5%/DEXTROSE 15% CLINIMIX E 5%/DEXTROSE 20% CLINIMIX E 5%/DEXTROSE 25% CLINISOL SF 15% CLOLAR CLOMIPRAMINE HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin.
9 Name Other COMBIPATCH HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. COSMEGEN CROMOLYN SODIUM CYCLOBENZAPRINE HCL HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. CYCLOPHOSPHAMIDE CYCLOSPORINE CYCLOSPORINE MODIFIED CYPROHEPTADINE HCL HRM - Cyproheptadine failed one (1) safer formulary alternative if available or provided clinical rationale why the safer formulary alternative is not age.prior Auth For perennial and seasonal allergic rhinitis, safer alternatives are: Levocetirizine, Desloratadine. For any other indications, trial of formulary alternatives are not required. CYTARABINE CYTARABINE AQUEOUS DACARBAZINE DACTINOMYCIN
10 Name Other DAUNORUBICIN HCL DAUNOXOME DECITABINE DEXRAZOXANE DEXTROSE 10%/NACL 0.45% DEXTROSE 5% /ELECTROLYTE #48 VIAFLEX DEXTROSE 10% FLEX CONTAINER DEXTROSE 10%/NACL 0.2% DEXTROSE 2.5%/SODIUM CHLORIDE 0.45% DEXTROSE 5% DEXTROSE 20% DEXTROSE 25% DEXTROSE 30% DEXTROSE 30% PARTIAL FILL DEXTROSE 40% DEXTROSE 50% DEXTROSE 70% DEXTROSE 5%/NACL 0.2%
11 Name Other DEXTROSE 5%/NACL 0.225% DEXTROSE 5%/NACL 0.3% DEXTROSE 5%/NACL 0.33% DEXTROSE 5%/NACL 0.45% DEXTROSE 5%/NACL 0.9% DEXTROSE 5%/POTASSIUM CHLORIDE 0.15% DIFICID DIFICID 18 years of age and older. 10 days DIGOX HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not DIGOXIN HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not DIPYRIDAMOLE HRM - Platelet Modifying nts Safer alternatives are: Clopidogrel, Warfarin, Jantoven, and Aggrenox. DOCEFREZ DOCETAXEL
12 Name Other DOXEPIN HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. DOXERCALCIFEROL DOXORUBICIN HCL DOXORUBICIN HCL LIPOSOME DRONABINOL DYSPORT DYSPORT Exclude when used for cosmetic purposes. 3 months EGRIFTA EGRIFTA All FDA-approved excluded from part D. Males must have a waist circumference of at least 95cm (37.5in) and a waist-to-hip ratio of at least Females must have a waist circumference of at least 94cm (37in) and a waist-to-hip ratio of at least Patients must have a baseline CT documenting increased visceral adipose tissue (VAT). Reauthorization is contingent upon ONE of the following: 1) decrease in VAT measured by CT scan or 2) reduction of waist circumference and waist-to-hip ratio from baseline measurement. Patient must be on a stable antiretroviral regimen for at least 8 weeks. ELIGARD to New Starts ELIGARD Patient must have failure, contraindication or intolerance to Trelstar before Eligard is authorized. BvsD Determination ELITEK ELLENCE ELOXATIN EMEND
13 Name Other Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) ENBREL IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) ENBREL SURECLICK IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. ENGERIX-B EPIRUBICIN HCL EPOGEN HEMATOPOIETICS For the indication of anemia, documentation of Hemoglobin less than 11, Hematocrit, transferrin saturation greater than 20%, and ferritin levels greater than 100 obtained over the last 3 months. 6 months BvD Determination. Patients must also have failure, contraindication or intolerance to Procrit or Aranesp before Epogen will be authorized. ERBITUX
14 Name Other ERGOLOID MESYLATES HRM - Antidementia nts Safer alternatives are: donepezil, galantamine and rivastigmine. ERWINAZE ESTRADIOL HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ESTRADIOL/NORETHI NDRONE ACETATE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ESTROPIPATE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. ETOPOPHOS ETOPOSIDE EXTAVIA IMMUNOMODULATO RS FABRAZYME FASLODEX
15 Name Other FEMHRT LOW DOSE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. FENTANYL CITRATE FENTANYL CITRATE ORAL TRANSMUCOSAL TRANSMUCOSAL FENTANYL CITRATE All FDA-approved Documentation from the medical record of diagnosis. 16 years of age and older for fentanyl citrate (lozenge/troche). 18 years of age and older for Enrollment in the Transmucosal Immediate- Release Fentanyl (TIRF) REMS Access program. Transmucosal fentanyl products will only be covered with documentation of breakthrough cancer pain. The patient must be currently receiving and be tolerant to opioid therapy for persistent cancer pain.the patient must be enrolled in the TIRF REMS Access program. FIRAZYR FIRAZYR Patient must have a confirmed diagnosis of HAE as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER of the following: 1) C1 inhibitor (C1INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test 2) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test. Authorized for patients 18 years of age and older. The patient must have a history of a moderate or severe attack (e.g., airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion). FIRMAGON FLEBOGAMMA FLUDARABINE PHOSPHATE FLUOROURACIL FOLOTYN FOSCARNET SODIUM FREAMINE HBC 6.9% FREAMINE III GAMASTAN S/D GAMMAGARD LIQUID GAMMAGARD S/D
16 Name Other GAMMAGARD S/D IGA LESS THAN 1MCG/ML GAMMAKED GAMMAPLEX GAMUNEX-C GANCICLOVIR GATTEX GATTEX As long as the patient requires TPN, 3 months up to. GAZYVA GEMCITABINE GEMCITABINE HCL GENGRAF GENOTROPIN GENOTROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Genotropin. GENOTROPIN MINIQUICK GENOTROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Genotropin. GILENYA GILENYA Gilenya will be used as monotherapy for the treatment of multiple sclerosis. Patients must also have failure, contraindication or intolerance to one of the following formulary alternatives Avonex, Copaxone, Extavia or Rebif before Gilenya will be authorized. GLASSIA Alpha-1 Proteinase Inhibitor Therapy All FDA-approved excluded from part D. Intravenous alpha1-proteinase inhibitor (human) is authorized for the treatment of congenital alpha1-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met: 1) alpha1-antitrypsin (AAT) concentration less than 80mg/dl or less than 11 micromolar and 2) obstructive lung disease as defined by a forced expiratory volume in one second (FEV1) of 30 to 65% of predicted or a rapid decline in lung function defined as a change in FEV1 of greater than 120ml per year. BvsD Determination.
17 Name Other GLYBURIDE HRM - Glyburide failed glipizide or provided clinical rationale as to why that safer formulary alternative is not GLYBURIDE MICRONIZED HRM - Glyburide failed glipizide or provided clinical rationale as to why that safer formulary alternative is not GRANISETRON HCL GRANISOL HARVONI Prior authorization applies HARVONI Previous failure of Harvoni Genotype, HCV RNA viral levels prior to treatment, documentation of presence/absence of cirrhosis Hepatologist, gastroenterologist, infectious disease specialist or managed by a liver transplant center 12 to 24 weeks based on indication and established treatment guidelines HECORIA HEPATAMINE HEPATASOL HERCEPTIN HIZENTRA HUMATROPE HUMATROPE COMBO PACK HUMATROPE HUMATROPE
18 Name Other Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) HUMIRA IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) HUMIRA PEN-CROHNS DISEASESTARTER IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) HUMIRA PEN- PEDIATRIC CROHNS DISEASESTARTER IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade.
19 Name Other Use of Humira, Enbrel, or Remicade is considered medically necessary for the treatment of: 1. Rheumatoid Arthritis in patients that have tried and failed methotrexate OR at least 2 alternative disease modifying antirheumatic drugs (DMARDs). 2. Juvenile Rheumatoid Arthritis in patients that have tried and failed at least 2 DMARDs. 3. Ankylosing Spondylitis in patients that have tried and failed at least 1 non-steroidal antiinflammatory drug (NSAID), corticosteroid, OR sulfasalazine. 4. Plaque Psoriasis in patients that have: a) moderate to severe chronic disease, b) minimum body surface area (BSA) involvement of greater than or equal to 5% OR involvement of the palms, soles, head, neck or genitalia, c) tried and failed at least 1 topical agent (topical steroid, calcipotriene, or tazarotene), AND d) tried and failed at least 1 systemic therapy (cyclosporine, methotrexate, or acitretin) OR phototherapy. 5. Psoriatic Arthritis in patients with active disease. In addition, use of Humira or Remicade is considered medically necessary for the treatment of: 1. Moderate to severe Crohn s Disease in patients that have tried and failed at least 2 of the following: immunomodulators, corticosteroids, or aminosalicylates. 2. Treatment of moderately to severely active ulcerative colitis in patients who have had inadequate response to at least 2 of the following: corticosteroids, sulfasalazine, mesalamine, azathioprine, 6-mercaptopurine. Use of Remicade will also be considered medically necessary for the treatment of fistulizing Crohn's disease. B vs D determination required for Remicade. HUMIRA PEN- PSORIASIS STARTER IMMUNE SUPPRESSANTS Documentation of diagnosis and past medication history. HYCAMTIN HYDROXYZINE HCL HRM - Hydroxyzine Oral For pruritus, safer alternatives are: Levocetirizine, Desloratadine. For anxiety, safer alternatives are: Buspirone, Fluoxetine, Paroxetine, Citalopram, and Venlafaxine. HYDROXYZINE HCL SOLUTION HRM - Hydroxyzine IM For anxiety, safer alternatives are: Buspirone, Fluoxetine, Paroxetine, Citalopram, and Venlafaxine. For nausea and vomiting, the safer alternative is ondansetron. HYDROXYZINE PAMOATE HRM - Hydroxyzine Oral For pruritus, safer alternatives are: Levocetirizine, Desloratadine. For anxiety, safer alternatives are: Buspirone, Fluoxetine, Paroxetine, Citalopram, and Venlafaxine. HYPERLYTE-CR IDAMYCIN PFS
20 Name Other IDARUBICIN HCL IFOSFAMIDE IFOSFAMIDE/MESNA ILARIS ILARIS BvsD Determination IMIPRAMINE HCL to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. IMIPRAMINE PAMOATE to New Starts HRM - Tricyclic Antidepressants Safer alternatives depend on indication. For Depression, safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. For headache prophylaxis, safer alternatives are: Propranolol, Topiramate, and Divalproex sodium. For headache treatment, safer alternatives are: Sumatriptan, Naratriptan, and Dihydroergotamine. For Pain/Neuropathy, safer alternatives are: Duloxetine, Lyrica, and Gabapentin. INCIVEK INCRELEX INCIVEK INCRELEX Documentation from the medical record of diagnosis including genotype, current medication regimen, and HCV-RNA levels. Documentation of diagnosis. Documentation of lab data reflecting height standard deviation score, basal IGF-1 score, and growth hormone level. Prescribing physician must be an endocrinologist. 12 weeks Concurrent therapy with peginterferon alfa and ribavirin is required for Incivek. Height standard deviation score must be less than or equal to -3.0 AND the basal IGF-1 score must be below the lower limits of normal for the reporting lab AND the patient must have a normal or elevated growth hormone level (excluding patients with growth hormone gene deletion) AND epiphyses must be confirmed as open in patients greater than or equal to 10 years of age. INDOMETHACIN HRM - Indomethacin Safer alternatives are: Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Nabumetone, Naproxen, Piroxicam, and Meloxicam.
21 Name Other INDOMETHACIN ER HRM - Indomethacin Safer alternatives are: Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Nabumetone, Naproxen, Piroxicam, and Meloxicam. INFERGEN INFERGEN Documentation of genotype to determine length of therapy. 6 months INTRALIPID INVEGA TRINZA to New Starts INVEGA TRINZA excluded from Part D Documentation of diagnosis and past medication history Use of Invega Sustenna for a minimum of 4 months is required prior to use of Invega Trinza. IONOSOL- B/DEXTROSE 5% IONOSOL- MB/DEXTROSE 5% IPRATROPIUM BROMIDE IPRATROPIUM BROMIDE/ALBUTERO L SULFATE IRINOTECAN ISOLYTE-P/DEXTROSE 5% ISOLYTE-S ISTODAX IXEMPRA KIT JEVTANA KABIVEN KADCYLA
22 Name Other KALBITOR KALBITOR Kalbitor is authorized for the treatment of acute angioedema attacks with hereditary angioedema (HAE) when BOTH of the following criteria are met: 1) confirmed diagnosis of (HAE) as evidenced by a C4 level below the lower limit of normal as defined by the laboratory performing the test AND EITHER a) C1 inhibitor (C1INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test or b) C1INH functional level below the lower limit of normal as defined by the laboratory performing the test AND 2) history of a moderate or severe attack (e.g., airway swelling, severe abdominal pain, facial swelling, nausea and vomiting, painful facial distortion). 16 years old and older KALYDECO KCL 0.075%/D5W/NACL 0.45% KALYDECO Patients with cystic fibrosis (CF) who are homozygous for the F508del mutation in the CFTR gene. CF mutation test documenting a G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R mutation in the CFTR gene. 6 years of age and older KCL 0.15%/D5W/LR KCL 0.15%/D5W/NACL 0.2% KCL 0.15%/D5W/NACL 0.225% KCL 0.15%/D5W/ NACL 0.3% KCL 0.15%/D5W/NACL 0.9% KCL 0.3%/D5W/NACL 0.45% KCL 0.3%/D5W/NACL 0.9% KCL 0.3%/D5W/LR IV LAC RING KEYTRUDA KORLYM LACTATED RINGERS DEXTROSE 5% VIAFLEX KORLYM
23 Name Other LANOXIN HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not LANOXIN PEDIATRIC HRM - Digoxin the physician has documented that the patient has tried digoxin 0.125mg daily or provided clinical rationale as to why the lower dose is not LAZANDA TRANSMUCOSAL FENTANYL CITRATE All FDA-approved Documentation from the medical record of diagnosis. 17 years of age and older for fentanyl citrate (lozenge/troche). 18 years of age and older for Lazanda. Enrollment in the Transmucosal Immediate- Release Fentanyl (TIRF) REMS Access program. Transmucosal fentanyl products will only be covered with documentation of breakthrough cancer pain. The patient must be currently receiving and be tolerant to opioid therapy for persistent cancer pain.the patient must be enrolled in the TIRF REMS Access program. LEUPROLIDE ACETATE to New Starts LEUPROLIDE ACETATE INJ For the treatment of prostate cancer, the patient must have failure, contraindication or intolerance to Trelstar before Lupron is authorized. BvsD Determination LEVALBUTEROL LEVALBUTEROL HCL LIDOCAINE LIDOCAINE PATCH For the FDA-labeled indication of postherpetic neuralgia, no additional criteria are required to be met. For OTHER types of offlabeled neuropathic pain: the patient must have previous use and inadequate response or intolerance to any ONE neuropathic pain medication, including (but not limited to) duloxetine and Lyrica that are labeled for neuropathic pain. LIPODOX LIPODOX 50 LIPOSYN II LIPOSYN III
24 Name Other LOPREEZA HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. LOTRONEX LUPRON DEPOT LUPRON DEPOT-PED LOTRONEX LEUPROLIDE ACETATE INJ LEUPROLIDE ACETATE INJ Lotronex (alosetron) will not be approved for use in men, as safety and efficacy in men has not been established. must be enrolled in the prescribing program for alosetron. For the treatment of prostate cancer, the patient must have failure, contraindication or intolerance to Trelstar before Lupron is authorized. BvsD Determination For the treatment of prostate cancer, the patient must have failure, contraindication or intolerance to Trelstar before Lupron is authorized. BvsD Determination MAGNESIUM SULFATE MAKENA MAKENA Makena is authorized to reduce the risk of preterm birth when ALL of the following are met: 1) current singleton pregnancy AND 2) previous singleton spontaneous preterm birth (preterm birth defined as birth from the period of viability through week 36, 6 days gestation) AND 3) treatment will be initiated between week 16, 0 days and week 20, 6 days of gestation and not continue beyond week 36, 6 days of gestation or time of delivery (whichever occurs first). up to 21 weeks BvsD Determination MARTEN-TAB HRM - Butalbital Combinations Safer alternatives are: naproxen sodium and ibuprofen. MEGACE ES HRM - Megestrol Suspension failed dronabinol or provided clinical rationale as to why that safer formulary alternative is not
25 Name Other MEGESTROL ACETATE SUSPENSION to New Starts HRM - Megestrol Suspension failed dronabinol or provided clinical rationale as to why that safer formulary alternative is not MEGESTROL ACETATE TABS to New Starts HRM - Megestrol Tabs documented the ongoing monitoring plan for the agent. age.prior Auth MELPHALAN HYDROCHLORIDE MENEST HRM - Menest failed one (1) safer formulary alternative or provided clinical rationale why the safer formulary alternative is not appropriate for the patient. For palliative therapy of metastatic breast cancer, no trial of a formulary alternative is required. age.prior Auth For vasomotor symptoms of menopause, safer alternatives are: SSRIs, venlafaxine, gabapentin, and Femring. For vaginal symptoms of menopause, safer alternatives are: Premarin Cream, Estring, and Femring. For all other indications, no formulary alternative is required. MENOSTAR HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. MESNA METHAMPHETAMINE HCL METHAMPHETAMINE HCL Patient must have failure, contraindication or intolerance to one formulary alternative such as dextroamphetamine, amphetamine/dextroamphetamine, methylphenidate or dexmethylphenidate before methamphetamine hcl is authorized.
26 Name Other MIMVEY HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. MITOMYCIN MITOXANTRONE HCL MODAFINIL MODAFINIL Documentation of diagnosis and sleep study for the diagnosis of sleep apnea or narcolepsy. For the treatment of narcolepsy, the patient must have failure, contraindication, or intolerance to methylphenidate or dextroamphetamine sulfate before modafinil is authorized. MUSTARGEN MYCOPHENOLATE MOFETIL MYCOPHENOLIC ACID DR MYFORTIC NAVELBINE NEBUPENT NEORAL NEPHRAMINE NEUMEGA NEUMEGA Documentation of diagnosis and lab data reflecting platelet count. Certified Hematologist and/or Oncologist up to 6 months Neumega is considered medically necessary for patients that have experienced severe thrombocytopenia (platelet count less than or equal to 20,000 mcg/l) from previous chemotherapy OR patients cosidered to be at high risk for the development of severe thrombocytopenia. BvsD Determination. NIPENT
27 Name Other NORDITROPIN FLEXPRO NORDITROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Norditropin. NORDITROPIN NORDIFLEX PEN NORDITROPIN For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Norditropin. NORETHINDRONE ACETATE/ETHINYL ESTRADIOL 2.5MCG; 0.5MG HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. NORMOSOL-M IN D5W NORMOSOL-R NORMOSOL-R IN D5W NULOJIX NUTRILIPID 20% IV FAT EMULSION NUTROPIN NUTROPIN For GHD in children or adults, Turner Syndrome, SGA or SHOX gene deletion, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Nutropin. NUTROPIN AQ NUSPIN 5 NUTROPIN For GHD in children or adults, Turner Syndrome, SGA or SHOX gene deletion, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Nutropin. NUTROPIN AQ PEN NUTROPIN For GHD in children or adults, Turner Syndrome, SGA or SHOX gene deletion, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Nutropin. NUVIGIL NUVIGIL Documentation of diagnosis and sleep study for the diagnosis of sleep apnea or narcolepsy. For the treatment of narcolepsy, the patient must have failure, contraindication, or intolerance to methylphenidate or dextroamphetamine sulfate before Nuvigil is authorized.
28 Name Other OCTAGAM OLYSIO OLYSIO Previous failure to respond to treatment with other HCV directacting protease inhibitors or Documentation from the medical record of diagnosis including repeated courses of simeprevir genotype, current medication regimen, and HCV-RNA levels. will result in exclusion of coverage for Olysio. 12 to 24 weeks based on indication and established treatment guidelines Concurrent therapy with peginterferon alfa and ribavirin is required for Olysio (unless Olysio is being used in combination with sofosbuvir). OMNITROPE OMNITROPE For GHD in children or adults, Turner Syndrome, SGA, SHOX gene deletion or growth delay in children with chronic kidney disease, the patient must have failure, contraindication or intolerance to Humatrope or Saizen before coverage of Omnitrope. ONCASPAR ONDANSETRON HCL ONDANSETRON ODT OPDIVO ORENCIA ORENCIA IV 6 years old and older Treatment of rheumatoid arthritis (RA) and when ANY of the following criteria are met: 1) history of positive clinical response to abatacept therapy OR 2) inadequate response, intolerance, or contraindication to at least one disease-modifying anti-rheumatic drug (DMARD) (i.e., Methotrexate (MTX) Azathioprine, gold, Hydroxychloroquine, Penicillamine, Sulfasalazine) AND when the following condition is met: the patient has had failure, contraindication, or intolerance to Enbrel or Humira. ORPHENADRINE CITRATE HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth ORPHENADRINE CITRATE ER HRM - Skeletal Muscle Relaxants documented the ongoing monitoring plan for the agent. age.prior Auth
29 Name Other OXALIPLATIN PACLITAXEL PAMIDRONATE DISODIUM PARICALCITOL PEG-INTRON PEG-INTRON REDIPEN PEG-INTRON PEG-INTRON Documentation of genotype to determine length of therapy. Documentation of genotype to determine length of therapy. 6 months 6 months PERFOROMIST PERIKABIVEN PERJETA PERPHENAZINE/AMIT RIPTYLINE to New Starts HRM - Perphenazine/Amitriptyli ne Safer alternatives are: Nortriptyline, Protriptyline, Desipramine, Amoxapine, Citalopram, Venlafaxine, Fluoxetine, Paroxetine, Sertraline, Duloxetine, and Bupropion. PHENADOZ HRM - Promethazine failed one (1) safer formulary alternative if available or provided clinical rationale why the safer formulary alternative is not age.prior Auth For nausea and vomiting, the safer alternative is ondansetron (QL = 90/30). For perennial and seasonal allergic rhinitis, safer alternatives are: levocetirizine and desloratadine. For any other indications, trial of a formulary alternative is not required. PHYSIOLYTE PHYSIOSOL IRRIGATION PLASMA-LYTE A PLASMA-LYTE-148
30 Name Other PLASMA-LYTE-56/D5W POTASSIUM CHLORIDE POTASSIUM CHLORIDE 0.15% /NACL 0.45% VIAFLEX POTASSIUM CHLORIDE 0.15% D5W/NACL 0.33% POTASSIUM CHLORIDE 0.15% D5W/NACL 0.45% POTASSIUM CHLORIDE 0.15%/NACL 0.9% POTASSIUM CHLORIDE 0.22% D5W/NACL 0.45% POTASSIUM CHLORIDE 0.3%/ NACL 0.9% POTASSIUM CHLORIDE 0.3%/D5W PREFEST HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PREMARIN HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PREMASOL
31 Name Other PREMPHASE HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PREMPRO HRM - Estrogens Safer alternatives to the estrogen high risk medications depend on the indication. For Hot Flashes, safer alternatives are: Estradiol Valerate, Depo-Estradiol, SSRIs, venlafaxine, gabapentin, and Femring. For Vaginal Symptoms, safer alternatives are: Premarin Cream, Estring, Femring, and Estradiol Valerate. For Bone Density, safer alternatives are: alendronate, risedronate, Evista, and Prolia. PRIALT PRIVIGEN PROCALAMINE PROCRIT HEMATOPOIETICS For the indication of anemia, documentation of Hemoglobin less than 11, Hematocrit, transferrin saturation greater than 20%, and ferritin levels greater than 100 obtained over the last 3 months. 6 months BvD Determination. Patients must also have failure, contraindication or intolerance to Procrit or Aranesp before Epogen will be authorized. PROGRAF PROLASTIN-C Alpha-1 Proteinase Inhibitor Therapy All FDA-approved excluded from part D. Intravenous alpha1-proteinase inhibitor (human) is authorized for the treatment of congenital alpha1-proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met: 1) alpha1-antitrypsin (AAT) concentration less than 80mg/dl or less than 11 micromolar and 2) obstructive lung disease as defined by a forced expiratory volume in one second (FEV1) of 30 to 65% of predicted or a rapid decline in lung function defined as a change in FEV1 of greater than 120ml per year. BvsD Determination. PROLEUKIN PROMETHAZINE HCL HRM - Promethazine failed one (1) safer formulary alternative if available or provided clinical rationale why the safer formulary alternative is not age.prior Auth For nausea and vomiting, the safer alternative is ondansetron (QL = 90/30). For perennial and seasonal allergic rhinitis, safer alternatives are: levocetirizine and desloratadine. For any other indications, trial of a formulary alternative is not required.
ACTEMRA. Cigna Medicare Rx (PDP) 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary. Products Affected Actemra. Prior Authorization Criteria
Cigna Medicare Rx (PDP) Medicare Part D Prescription Drug Plans 2014 Cigna Medicare Rx Secure Plan (PDP) Formulary Prior Authorization ACTEMRA Products Affected Actemra PA Details Age Other Authorization
More information2016 Cigna-HealthSpring Prior Authorization Criteria (Updated August 2016)
2016 Cigna-HealthSpring Criteria (Updated August 2016) Drug Name Type Description Product Group Covered Uses Exclusion Criteria Required Medical Information Age Restrictions Prescriber Restrictions Coverage
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
November 1, 2014 Bulletin #150 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary New Exception Drug Status (EDS) Listings Effective November 1, 2014
More informationDrugs covered under Medicare Part B or Part D
LABEL_NAME GENERIC_NAME MESSAGE GEMZAR INJ 1 GM GEMCITABINE HCL FOR INJ 1 GM ALIMTA INJ 500MG PEMETREXED DISODIUM FOR IV SOLN 500 MG (BASE EQUIV) FUNGIZONE INJ 50MG AMPHOTERICIN B FOR INJ 50 MG KYTRIL
More informationSTAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12
STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What
More informationPrior Authorization FID 16157 VER.7 UPDATED 8/2015
Prior Authorization FID 16157 VER.7 UPDATED 8/2015 Prior Authorization 2016 MAPD Leon 3 Tier Last Updated: 10/22/2015 ACTEMRA Products Affected Actemra INJ 162MG/0.9ML PA Details Other 1 ACTIMMUNE Products
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationAlameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION
Alameda Alliance for Health SPECIALTY PHARMACY PROGRAM FOR ALLIANCE MEDI-CAL AND GROUP CARE MEMBERS PROGRAM DESCRIPTION Contents Page Program Overview 1 Process for Obtaining Authorization 2 Contacts 2
More informationN/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative
Actimmune Amlodipine Androderm Anticonvulsant Antidepressants Antineoplastics Antipsychotics Arcalyst Butalbital Colony Stimulating Factors ESRD Therapy Actimmune Norvasc Androderm Banzel Keppra Mysoline
More informationMedications for chronic pain
Medications for chronic pain When it comes to treating chronic pain with medications, there are many to choose from. Different types of pain medications are used for different pain conditions. You may
More informationsubcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationDISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS
DISEASE-MODIFYING ANTIRHEUMATIC DRUG THERAPY FOR RHEUMATOID ARTHRITIS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE NCQA APPROVED CODES HEDIS
More informationSovaldi (sofosbuvir) Prior Authorization Criteria
INITIAL REVIEW CRITERIA Sovaldi (sofosbuvir) Prior Authorization Criteria 1. Adult patient age 18 years old; AND 2. Prescribed by a hepatologist, gastroenterologist, infectious disease specialist, transplant
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationSECTION 3. Criteria for Special Authorization of Select Drug Products. Section 3 Criteria for Special Authorization of Select Drug Products
SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The
More informationHydration, IV Infusions, Injections and Vaccine Charge Process
There are a number of items to be considered when billing for the Nursing service to perform drug therapy, the charge process is divided into three specific groups of codes and processes. 1. Hydration
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationMEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This
More informationACTEMRA. Step Therapy Criteria HEALTH CHOICE EXCHANGE 2016 Effective Date: 01/01/2016. PRODUCT(s) AFFECTED ACTEMRA
ACTEMRA ACTEMRA Claim will pay automatically for Actemra if enrollee has a paid claim for at least a 1 days supply of Enbrel and Humira in the past 365 days. Otherwise, Actemra requires a step therapy
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationPrior Authorization Form
Prior Authorization Form Growth Hormone This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS/Caremark at
More informationArthritis and Rheumatology Clinics of Kansas Patient Education. Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis
Arthritis and Rheumatology Clinics of Kansas Patient Education Reactive Arthritis (ReA) / Inflammatory Bowel Disease (IBD) Arthritis Introduction: For as long as scientists have studied rheumatic disease,
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationMOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
More informationCo-pay assistance organizations offering assistance
Acromegaly Acute Exacerbations of Multiple Sclerosis Acute Porphyrias Advanced Idiopathic Parkinson' s Disease Age-Related Macular Degeneration www.theassistancefund.org Alcohol Dependence Alpha-1 Antitrypsin
More information2016 Prior Authorization Requirements
Group Health Medicare Advantage HMO 2016 PLEASE READ: Group Health requires you to get prior authorization for certain drugs. This means that you will need to get approval from Group Health before you
More information2014 Valley Baptist Medicare D Formulary Step Therapy Criteria
2014 Valley Baptist Medicare D Formulary Step Therapy Products Affected ACTONEL TAB Last Updated 11/1/2014 Requires a trial of alendronate. 1 APLENZIN TAB Patient must have tried bupropion SR or bupropion
More informationMEDICATION GUIDE. ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Solution for Intravenous Infusion ACTEMRA (AC-TEM-RA) (tocilizumab) Injection, Solution for Subcutaneous Administration Read this Medication Guide before
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationPRACTICAL HELP FROM THE ARTHRITIS FOUNDATION. www.arthritis.org 800-283-7800. Psoriatic Arthritis
Psoriatic Arthritis WHAT IS PSORIATIC ARTHRITIS? Psoriatic (sore-ee-aah-tick) arthritis is a condition that causes pain and swelling in joints and scaly patches on the skin. Psoriatic arthritis occurs
More informationNDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only
Updated 5.5.14 NDC HCPCS HCPCS Description NDC Description Effective Date End Date X-Over Only 68152-0103-03 A9543 YTTRIUM Y-90 IBRITUMOMAB TIUXETAN ZEVALIN Y-90 VIAL 9/1/2013 12/31/2013 50419-0320-05
More informationLupus in Children and Teenagers. Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital
Lupus in Children and Teenagers Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital Systemic Lupus Erythematosus (SLE) Chronic Illness What is lupus? Autoimmune Multisystem Antinuclear
More informationTREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
More informationArthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke
Reading Comprehension Read the following essay on juvenile rheumatoid arthritis. Then use the information in the text to answer the questions that follow. Arthritis in Children: Juvenile Rheumatoid Arthritis
More informationRheumatoid Arthritis Information
Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative
More informationPreventing and Treating Nausea and Vomiting Caused by Cancer Treatment
A Patient s Guide Preventing and Treating Nausea and Vomiting Caused by Cancer Treatment Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is
More informationNUVIGIL (armodafinil) oral tablet
NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationRheumatoid Arthritis
Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly
More informationfor Extended Stability Parenteral Drugs Third Edition Caryn M. Bing, R.Ph., M.S., FASHP Editor
Extended Stability for Parenteral Drugs Third Edition Editor Caryn M. Bing, R.Ph., M.S., FASHP 1 American Society of Health-System Pharmacists Bethesda, Maryland Contents Preface Acknowledgments x/ Dedication
More informationDrugs Requiring Prior Authorization. Olysio. Subsys. Prolia. Tecfidera
Abstral Acthar Hp Adcirca Adempas Affinitor Amitiza Amitriptyline Ampyra Androgel Androderm Androxy Aranesp Arcalyst Aubagio Avonex Bosulif Bydureon Byetta Cimzia Cinryze Clomipramine Cometriq Copaxone
More informationDrug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
More informationDrugs That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS
That Require Prior Authorization (PA) Before Being Approved for Coverage PRIOR AUTHORIZATION MEDICATIONS ACNE Approve for those 12 years of age and older AVITA, RETIN-A MICRO, TRETINOIN ACTHAR HP All FDA-approved
More informationRheumatoid Arthritis
What is Rheumatoid Arthritis? Rheumatoid Arthritis (RA) is a chronic and systemic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints
More informationOverview of Rheumatology
Overview of Rheumatology Griffin Hospital Mini Med School Stephen Moses, MD Valley Medical Associates 135 Division St. Ansonia, CT 06401 203.735.9354 Topics I. Anatomy of a Joint II. Osteoarthritis III.
More informationCLINICAL POLICY Department: Medical Management Document Name: Rheumatoid & Juvenile Arthritis and Ankylosing Spondylitis Treatments
Page: 1 of 18 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationSPECIAL AUTHORIZATION GUIDELINES
91B ALBERTA DRUG BENEFIT LIST SPECIAL AUTHORIZATION GUIDELINES 37BSpecial Authorization Policy 90BDrug Products Eligible for Consideration by Special Authorization Drug Products may be considered for coverage
More informationPrior Authorization Requirements. Effective: 01/01/2016
Effective: 01/01/2016 Updated 11/2015 5HT3 ANTI-NAUSEA AGENT BVD DETERMINATION GRANISETRON HCL ONDANSETRON HCL ONDANSETRON ODT THIS DRUG MAY BE COVERED UNDER MEDICARE PART B OR D DEPENDING UPON THE CIRCUMSTANCES.
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationPlan Year 2016. Vantage Health Plan (HMO) Prior Authorization (PA) Criteria
Plan Year 2016 Vantage Health Plan (HMO) Prior Authorization (PA) Criteria Prior Authorization: Vantage Health Plan requires you (or your physician) to get prior authorization for certain drugs. This means
More informationFor renewals, patient must have responded to Actemra therapy (e.g., condition improved or stabilized).
PA Criteria ACTEMRA ACTEMRA Active infection (including TB). Concurrent therapy with other biologic agent(s). Screening for latent tuberculosis is required. If results are positive, patient must have completed
More informationGrowth Hormone Deficiency
Growth Hormone Deficiency What is growth hormone deficiency? 1,2 Growth hormone deficiency is when your body doesn t make enough growth hormone. Growth hormone is one of many hormones made by the pituitary
More informationMedicines for Psoriatic Arthritis. A Review of the Research for Adults
Medicines for Psoriatic Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this information is right for you if: Your doctor* has told you that you have psoriatic (pronounced
More informationMedicines for Rheumatoid. Arthritis. A Review of the Research for Adults
Medicines for Rheumatoid Arthritis A Review of the Research for Adults Is This Information Right for Me? Yes, this summary is for you if: Your doctor* has told you that you have rheumatoid (pronounced
More informationHome Delivery Prescription Program Drug List
Home Delivery Prescription Program Drug List Low-cost prescriptions, right in your mailbox. Now you can have your generic prescriptions mailed right to your home, no matter where you live. Because we think
More informationMedications most likely to be seen in primary care
Hazardous Medicines The majority of medicines are not classed as hazardous. The only medicinal products that are automatically deemed to be hazardous are cytotoxic and cytostatic medicines. There is no
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationHealthPartners, Inc. 2013 Medicare Part D Formulary ID 13142, Version 22 Prior Authorization Criteria. Last Updated: 11/01/2013
ACTEMRA Actemra (1) DIAGNOSIS OF MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS, OR (2) JUVENILE IDIOPATHIC ARTHRITIS, AND (3) DOCUMENTATION OF MEDICAL CONTRAINDICATIONS OR FAILURE WITH ENBREL OR HUMIRA.
More informationPOST-TEST Pain Resource Professional Training Program University of Wisconsin Hospital & Clinics
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
More informationDepartment of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014
Department of Vermont Health Access Pharmacy Benefit Management Program DUR Board Meeting Minutes: 03/11/2014 Board Members: Present: Joseph Lasek, MD, Chair Gary Starecheski, RPh Mark Pasanen, MD James
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr REMICADE (Infliximab) This leaflet is part III of a three-part "Product Monograph" published when REMICADE was approved for sale in Canada and is designed specifically
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationCurrent Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
More informationMedications to Prevent and Treat Osteoporosis
Medications to Prevent and Treat Osteoporosis National Institutes of Health Osteoporosis and Related Bone Diseases ~ National Resource Center 2 AMS Circle Bethesda, MD 20892-3676 Tel: (800) 624-BONE or
More informationPrior Authorization Requirements Effective: 12/01/2015
An Independent Licensee of the Blue Cross and Blue Shield Association Prior Authorization Requirements Effective: 12/01/2015 No changes made since 10/2015 AMPYRA AMPYRA PLUS PATIENT ALREADY STARTED ON
More informationBreast Cancer. Breast Cancer Page 1
Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or
More informationPrior Authorization Requirements. Effective: 12/01/2015
Effective: 12/01/2015 Updated 11/2015 ABILIFY MAINTENA ABILIFY MAINTENA DIAGNOSIS OF SCHIZOPHRENIA MUST BE 18 YEARS OF AGE OR OLDER DOCUMENTED HISTORY OF POOR ADHERENCE TO ORAL MEDICATIONS AND DOCUMENTATION
More informationPsoriatic arthritis FACTSHEET
1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have
More informationPrior Authorization Criteria 2014
Prior Authorization Criteria 2014 For information on obtaining an updated coverage determination or an exception to a coverage determination please contact Easy Choice Health Plan of New York s Member
More informationPREFERRED GENERIC DRUG LIST
These discount programs are NOT health insurance policies and are not intended as a substitute for insurance. The programs do not qualify as a minimum creditable coverage under Massachusetts law or where
More informationPsoriasis and Psoriatic Arthritis Alliance
Psoriasis and Psoriatic Arthritis Alliance A principal source of information on psoriasis and psoriatic arthritis ) Treatments for Psoriatic Arthritis overview Although psoriatic arthritis is a chronic
More informationPrior Authorization Requirements. Effective: 01/01/2016
Effective: 01/01/2016 H2986_PD_048 Updated 11/2015 5HT3 ANTI-NAUSEA AGENT BVD DETERMINATION ANZEMET GRANISETRON HCL ONDANSETRON HCL ONDANSETRON ODT ZOFRAN ZOFRAN ODT ZUPLENZ THIS DRUG MAY BE COVERED UNDER
More informationHow To Take Methotrexate By Injection
How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate
More informationProducts Affected Aralast Np INJ 400MG Glassia
Prior Authorization CCA SCO 2016 Last Updated: 10/2015 Effective date : January 1, 2016 AAT INHIBITORS (S) Products Affected Aralast Np INJ 400MG Glassia Prolastin-c Zemaira PA Age Other IgA deficiency
More informationCytokine and CAM Antagonists
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Actemra (Tocilizumab) Drugs requiring prior authorization: the list of drugs
More informationFDA Approved Indications
Preferred Agents: Humatrope (somatropin) Nutropin (somatropin) Medication Nutropin AQ (somatropin) Nutropin AQ NuSpin (somatropin) Non-Preferred Agents: Genotropin (somatropin) Omnitrope (somatropin) Norditropin
More informationNATIONAL PSORIASIS FOUNDATION SYSTEMIC MEDICATIONS. for psoriasis and psoriatic arthritis including biologics and new oral treatments
NATIONAL PSORIASIS FOUNDATION SYSTEMIC MEDICATIONS for psoriasis and psoriatic arthritis including biologics and new oral treatments Introduction to psoriasis and psoriatic arthritis WHAT IS PSORIASIS?
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationMedicare Part D Drugs Requiring Prior Authorization
Formulary ID 14068, Version 17 Last Updated 11/2014 Y0051_1622_508 Accepted 09/14/2012 Medicare Part D Drugs Requiring Prior Authorization MVP Health Care requires you or your doctor to get prior authorization
More informationMember Rights & Responsibilities
Member Rights & Responsibilities Member Rights and Responsibilities Blue KC has updated our Member Rights & Responsibilities to be consistent across all of our HMO and PPO products. Blue KC members have:
More informationGuidelines for the Management of. Nausea and Vomiting in Cancer Patients
Guidelines for the Management of Nausea and Vomiting in Cancer Patients Guidelines for the Management of Nausea and Vomiting in Cancer Patients Management of chemotherapy-induced nausea and vomiting includes
More informationEfficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women
Efficacy and Tolerability of Antidepressant Duloxetine for Treatment of Hot Flushes in Menopausal Women Irina Shestakova, MD, PhD Research Center of Obstetrics, Gynecology and Perinatology Department of
More informationEmergency and inpatient treatment of migraine: An American Headache Society
Emergency and inpatient treatment of migraine: An American Headache Society survey. The objective of this study was to determine the practice preferences of AHS members for acute migraine treatment in
More informationRetail Prescription Program Drug List
Retail Prescription Program Drug List Price Matters New Men s Health Category Convenience Free Home Delivery Our 4 prescriptions have saved our customers over 3 billion The program is available to everyone,
More informationpåçííáëü=jéçáåáåéë=`çåëçêíáìã==
påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults
More informationRheumatoid Arthritis Medicines. A Guide for Adults
Rheumatoid Arthritis Medicines A Guide for Adults Fast Facts Medicines for rheumatoid arthritis (RA) can slow down the disease and reduce damage to joints. They can relieve pain and make it easier to do
More informationPainkillers (analgesics)
Drug information (analgesics) This leaflet provides information on painkillers and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets entirely
More information612 Program Midtown Express Pharmacy
ALENDRONATE SOD TAB 35MG (max 1 per week) $37.00 $70.00 ALENDRONATE SOD TAB 70MG (max 1 per week) $37.00 $70.00 ALLOPURINOL TAB 100MG $20.00 $38.00 ALLOPURINOL TAB 300MG $20.00 $38.00 AMITRIPTYLINE TAB
More informationArthritis www.patientedu.org
written by Harvard Medical School Arthritis www.patientedu.org Arthritis is the most common chronic disease in the world, and it s the leading cause of disability in the United States. There are more than
More information